With the numbers and cases of diabetes always on the rise with no end in sight, our biopharmaceutical company in East Windsor, New Jersey, decided to take action and do something about this global epidemic. Today, ARKAY Therapeutics is dedicated to developing and commercializing innovative medicines for Type 2 diabetes and preventing the onset of Type 2 diabetes in prediabetes patients.
More than 370 million people worldwide and 26 million people in the U.S. alone suffer from Type 2 diabetes. The disease is not successfully controlled in almost 50% of patients, according to American Diabetes Association.
The potential impact of our diabetes medicine has enormous medical and financial implications. This is an avenue that investors can’t afford to miss.
Learn More About ARKAY Therapeutics